United Therapeutics Corporation (UTHR) Stock

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation is led by CEO Martine A. Rothblatt, employs 1,305 people, headquartered in Silver Spring, US, publicly traded since 1999.

United Therapeutics Corporation (UTHR) stock trades at $524.70 with a market capitalization of $22.27B. The stock is valued at a price-to-earnings (P/E) ratio of 20.34, price-to-book of 3.93, price-to-sales of 7.36. Over the past 52 weeks the stock has ranged between $272.12 and $609.35, and currently trades 13.9% below its 52-week high.

On profitability, United Therapeutics Corporation generates a return on equity (ROE) of 20.26% — well above the market average, a sign of a high-quality business, return on capital employed of 21.38%, an operating margin of 45.34%, a net profit margin of 40.61%.

In its most recent fiscal year, United Therapeutics Corporation reported annual revenue of $3.2B, net profit of $1.3B, revenue has compounded at 16.5% a year over the last five years, profit at 21.0% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.00 — a conservative balance sheet with little leverage risk, a current ratio of 6.60, total assets of $7.9B, $1.6B in cash and equivalents.

UTHR has an average daily trading volume of 470,370 shares, a beta of 0.57 (less volatile than the overall market).

Official website: www.unither.com